Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 31.5% in October

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 54,700 shares, a drop of 31.5% from the October 15th total of 79,900 shares. Approximately 4.1% of the shares of the company are short sold. Based on an average daily trading volume, of 181,100 shares, the days-to-cover ratio is currently 0.3 days.

Sonoma Pharmaceuticals Trading Down 0.8 %

SNOA traded down $0.02 on Friday, reaching $2.56. The stock had a trading volume of 15,310 shares, compared to its average volume of 159,561. The business’s 50-day moving average price is $3.08 and its two-hundred day moving average price is $1.35. The company has a market cap of $3.43 million, a P/E ratio of -0.51 and a beta of 1.38. Sonoma Pharmaceuticals has a 12-month low of $2.52 and a 12-month high of $9.37.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.